Live tape
Top 8, mentions 7d30,017NVDA14,564 mentions▲ +0.04ANT4,160 mentions▲ +0.06GOOGL2,936 mentions▲ +0.04SPY2,248 mentions▲ +0.05QQQ1,804 mentions▲ +0.04SPCX1,748 mentions▲ +0.08AMD1,367 mentions▲ +0.06AAPL1,190 mentions▲ +0.04

Equity · Healthcare

ARWR

NASDAQ

Arrowhead Pharmaceuticals (ARWR)

41.39 USD −5.13% vs prior close Nov 20, 2026
Arrowhead Pharmaceuticals, Inc. price graph
64 sessions
100 40 24 Aug 20 Nov

The line runs 86.78 USD on 24 August through 41.39 USD on 20 November, on a scale from 40 to 100. Days the market did not trade hold the previous close, flat.

Market cap
5.9B USD
Revenue, year to Sep 2026
450.8M USD
EPS, diluted, year to Sep 2026
−5.11 USD
52-week range
38.09 USD – 89.61 USD
Avg volume
132.4K

as of Nov 20, 2026

Have Arrowhead Pharmaceuticals (ARWR) insiders bought or sold shares recently?

ARWR's newest Form 4 filing is dated 18 August 2026: none in the last 90 days.

Form 4

Have Arrowhead Pharmaceuticals (ARWR) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
18 Aug 2026OLUKOTUN ADEOYE YDirectorSell2,000174K USD
18 Aug 2026PERRY MICHAEL SDirectorSell11,6001.0M USD
12 May 2026Lu HongboDirectorSell2,970228K USD
23 Apr 2026Hamilton James CChief Medical OfficerSell10,000750K USD
22 Apr 2026Apel Daniel JosephChief Financial OfficerSell13,095934K USD
05 Mar 2026Hamilton James CChief Medical OfficerSell10,000642K USD
05 Jan 2026O'Brien PatrickCOOSell49,4933.1M USD
05 Jan 2026Hamilton James CChief Medical OfficerSell40,1642.5M USD
02 Jan 2026Anzalone Christopher RichardChief Executive OfficerSell13,187872K USD
29 Dec 2025Anzalone Christopher RichardChief Executive OfficerSell51,7263.6M USD
26 Dec 2025Ferrari MauroDirectorSell7,530527K USD
22 Dec 2025Anzalone Christopher RichardChief Executive OfficerSell12,586861K USD
Sold21 open-market sales560,501$37.34M

Showing the 12 most recent of 21 open-market trades in this window. The figures above count all of them.

15 other filings: grants, exercises, tax withholding and transfers, not trades
Have Arrowhead Pharmaceuticals (ARWR) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
15 Jun 2026Cohen Matthew GregoryDirectorAward11,882
06 Jan 2026O'Brien PatrickCOOGift2,500
06 Jan 2026O'Brien PatrickCOOAward75,000
06 Jan 2026Hamilton James CChief Medical OfficerAward75,000
06 Jan 2026Apel Daniel JosephChief Financial OfficerAward75,000
31 Dec 2025O'Brien PatrickCOOGift2,800
29 Dec 2025Anzalone Christopher RichardChief Executive OfficerOption exercise51,726318K USD
16 Dec 2025INGRAM DOUGLAS SDirectorAward7,819
16 Dec 2025OLUKOTUN ADEOYE YDirectorAward7,819
16 Dec 2025PERRY MICHAEL SDirectorAward7,819
16 Dec 2025Ferrari MauroDirectorAward7,819
16 Dec 2025Waddill William D.DirectorAward7,819

Showing the 12 most recent of 15 compensation filings in this window. The figures above count all of them.

Which funds hold Arrowhead Pharmaceuticals (ARWR)?

12 of the 45 institutional funds we track reported a Arrowhead Pharmaceuticals position for the quarter ended 30 Sep 2026 — a combined 383.0M USD; the latest of those filings landed 16 Nov 2026.

Form 13F

Which funds hold Arrowhead Pharmaceuticals (ARWR)?
FundPositionSharesValueShares q/q
Baker Bros. AdvisorsHeld (±25%)1,709,053111.9M USD−14.2%
Two Sigma InvestmentsAdded1,083,43270.9M USD+86.6%
Fisher Asset ManagementHeld (±25%)893,70058.5M USD−6.7%
Balyasny Asset ManagementAdded695,88345.5M USD+47.8%
Millennium ManagementAdded497,58732.6M USD+51.1%
Marshall WaceHeld (±25%)306,49120.1M USD+0.5%
AQR Capital ManagementHeld (±25%)213,58214.0M USD+7.4%
Citadel AdvisorsNew position197,65612.9M USD
D. E. Shaw & Co.Trimmed158,71910.4M USD−63.2%
Man GroupNew position51,1063.3M USD

Showing the 10 largest of 12 reported positions. The figures above count all of them.

Have members of Congress traded Arrowhead Pharmaceuticals (ARWR)?

The most recent congressional trade disclosed in Arrowhead Pharmaceuticals is a sale by Daniel S. Goldman (house, NY), dated 31 Jan 2023.

STOCK Act disclosures

Have members of Congress traded Arrowhead Pharmaceuticals (ARWR)?
TradedMemberTypeAmountFiled after
31 Jan 2023Daniel S. Goldmanhouse · Democrat–NYSale1K USD–15K USD24 days

What has been filed or recorded for Arrowhead Pharmaceuticals (ARWR)?

The filings we hold for Arrowhead Pharmaceuticals, newest first: 1 fails-to-deliver day, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 08 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Arrowhead Pharmaceuticals (ARWR)?
And
08 Oct 2026Fails to deliverShares failed to deliver540 shares33K USD notional · <0.001% of shares out
30 Sep 2026Annual reportFY 2026 reportedEPS −5.11 USD
30 Sep 2026FinancialsRevenue450.8M USDfiscal year
30 Sep 2026FinancialsNet income−724.2M USDfiscal year
30 Sep 2026FinancialsDiluted EPS−5.11 USDfiscal year
30 Sep 2026FinancialsTotal assets1.7B USDat period end
30 Sep 2026FinancialsTotal equity50.3M USDat period end
30 Jun 2026Quarterly earningsQ3 2026 reportedEPS −1.36 USD
31 Mar 2026Quarterly earningsQ2 2026 reportedEPS −0.93 USD
31 Dec 2025Quarterly earningsQ1 2026 reportedEPS 0.22 USD
30 Sep 2025Annual reportFY 2025 reportedEPS −0.01 USD
30 Jun 2025Quarterly earningsQ3 2025 reportedEPS −1.26 USD
31 Mar 2025Quarterly earningsQ2 2025 reportedEPS 2.75 USD
31 Dec 2024Quarterly earningsQ1 2025 reportedEPS −1.39 USD

What do people ask about Arrowhead Pharmaceuticals (ARWR)?

From live data
What did Arrowhead Pharmaceuticals shares close at?41.39

Arrowhead Pharmaceuticals closed at 41.39 USD on 20 Nov 2026, down 5.13% on the close before. That is the end-of-day price from Finazon, not a live quote.

What is Arrowhead Pharmaceuticals’ market cap?5.9B

Arrowhead Pharmaceuticals is worth 5.9B USD by market value as of 20 Nov 2026, which is the share price times the shares on issue from its SEC filings.

What is Arrowhead Pharmaceuticals’ revenue?450.8M

Arrowhead Pharmaceuticals reported revenue of 450.8M USD for the year ended 30 Sep 2026, as filed with the SEC. See Filings

Have Arrowhead Pharmaceuticals insiders bought or sold shares recently?

No Arrowhead Pharmaceuticals insider has filed a Form 4 in the last 90 days; the most recent filing we hold is dated 18 Aug 2026 (SEC Form 4). See Insiders

Which funds own Arrowhead Pharmaceuticals?12 of 45

12 of the 45 funds we track reported a Arrowhead Pharmaceuticals position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Baker Bros. Advisors, Two Sigma Investments and Fisher Asset Management. See Funds

Have members of Congress traded Arrowhead Pharmaceuticals?1 trade

Yes. 1 trade in Arrowhead Pharmaceuticals appears in the congressional disclosures we hold: a sale by Daniel S. Goldman (House, NY) dated 31 Jan 2023, filed 24 Feb 2023. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress

When did Arrowhead Pharmaceuticals last report earnings?−5.11

Arrowhead Pharmaceuticals last reported earnings on 30 Sep 2026 for FY 2026, with EPS of −5.11 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. Wikimedia CommonsPortraits via Wikimedia Commons. Daniel S. Goldman: US House, Public domain.
  6. House disclosuresU.S. House of Representatives financial disclosures
  7. SECSEC fails-to-deliver (CNS) data
  8. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  9. SEC EDGARreported earnings figures and scheduled report dates
  10. SEC EDGARValuation computed from SEC EDGAR filings
  11. SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words